Emerging Endoscopic Therapies for Weight Loss

  • Thomas J. Wang
  • Marvin RyouEmail author


The prevalence of obesity and metabolic disease continues to rise in the United States and around the world. Efforts to combat this growing pandemic have utilized a multipronged strategy, including promoting public education, implementing public health measures, and focusing on a multidisciplinary treatment approach integrating nutrition, psychology, medicine, and surgery. Another component of this multipronged strategy has been the development of endoscopic therapeutic options less invasive than surgery. Currently, there are four FDA-approved devices, including three intra-gastric balloons and an aspiration device, which are discussed in a prior chapter. This chapter will focus on emerging endoscopic interventions for weight loss and metabolic therapies currently in development and/or undergoing clinical trials.


Endoscopic devices Bariatric therapy Weight loss Metabolic disease Non-FDA-approved devices Gastroduodenal implant Malabsorptive sleeve Gastric motility Intestinal alterations 


  1. 1.
    National Center for Health Statistics. National Health and Nutrition Examination Survey. 2014. URL: [accessed 2014-09-08][WebCite Cache]. 2014.
  2. 2.
    Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–31.CrossRefGoogle Scholar
  3. 3.
    Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31(1):219–30.CrossRefGoogle Scholar
  4. 4.
    Ma IT, Madura JA. Gastrointestinal complications after bariatric surgery. Gastroenterol Hepatol. 2015;11(8):526.Google Scholar
  5. 5.
    Ryou M, McQuaid KR, Thompson CC, Edmundowicz S, Mergener K, Force AE. ASGE EndoVators Summit: defining the role and value of endoscopic therapies in obesity management. Obesity surgery. 2018;28(1):3–14.CrossRefGoogle Scholar
  6. 6.
    Marinos G, Eliades C, Muthusamy VR, Greenway F. Weight loss and improved quality of life with a nonsurgical endoscopic treatment for obesity: clinical results from a 3-and 6-month study. Surg Obes Relat Dis. 2014;10(5):929–34.CrossRefGoogle Scholar
  7. 7.
    Densford F. BaroNova touts TransPyloric Shuttle pivotal study data. In: MassDevice Medical Network. 2018. Accessed 21 July 2019.
  8. 8.
    Densford F. BaroNova wins FDA nod for TransPyloric Shuttle weight loss device. In: MassDevice Medical Network. 2019. Accessed 21 July 2019.
  9. 9.
    Sauer N, Rösch T, Pezold J, Reining F, Anders M, Groth S, Schachschal G, Mann O, Aberle J. A new endoscopically implantable device (SatiSphere) for treatment of obesity—efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 levels. Obes Surg. 2013;23(11):1727–33.CrossRefGoogle Scholar
  10. 10.
    Gersin KS, Rothstein RI, Rosenthal RJ, Stefanidis D, Deal SE, Kuwada TS, Laycock W, Adrales G, Vassiliou M, Szomstein S, Heller S. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976–82.CrossRefGoogle Scholar
  11. 11.
    Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984–92.CrossRefGoogle Scholar
  12. 12.
    Cohen RV, et al. A pilot study of the duodenal-jejunal bypass liner in low body mass index type 2 diabetes. J Clin Endocrinol Metab. 2013;98:E279–82.CrossRefGoogle Scholar
  13. 13.
    Sen Gupta P, Drummond RS, Lugg ST, McGowan BM, Amiel SA, Ryder RE. One year efficacy, safety and tolerability outcomes of endoscopic duodenal exclusion using EndoBarrier as an adjunct to glucagon-like peptide-1 (GLP-1) therapy in suboptimally controlled type 2 diabetes: a randomised controlled trial. In Novel treatment for diabetes-focusing on GLP-1 and SGLT2. Endocrine Society; 2016. p. PP15–PP11.
  14. 14.
    Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK. Effect of the EndoBarrier gastrointestinal liner on obesity and type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2016;18(3):300–5.CrossRefGoogle Scholar
  15. 15.
    Safety and efficacy of EndoBarrier in subjects with type 2 diabetes who are obese. In: 2016. Accessed 22 Oct 2017.
  16. 16.
    Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini M, Horgan S. Human experience with an endoluminal, endoscopic, gastrojejunal bypass sleeve. Surg Endosc. 2011;25(9):3028–33.CrossRefGoogle Scholar
  17. 17.
    Sandler BJ, Rumbaut R, Swain CP, Torres G, Morales L, Gonzales L, Schultz S, Talamini MA, Jacobsen GR, Horgan S. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for morbid obesity. Surg Endosc. 2015;29(11):3298–303.CrossRefGoogle Scholar
  18. 18.
    The ValenTx endo bypass system in obese subjects. In: 2016. Accessed 22 Oct 2017.
  19. 19.
    Lacy BE, Weiser K, Kennedy A. Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol. 2008;4(4):283.Google Scholar
  20. 20.
    Pero R, Coretti L, Lembo F. Botulinum toxin a for controlling obesity. Toxins. 2016;8(10):281.CrossRefGoogle Scholar
  21. 21.
    Foschi D, Corsi F, Lazzaroni M, Sangaletti O, Riva P, La Tartara G, Bevilacqua M, Osio M, Alciati A, Bianchi Porro G, Trabucchi E. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study. Int J Obes. 2007;31(4):707.CrossRefGoogle Scholar
  22. 22.
    Gui D, Mingrone G, Valenza V, Spada PL, Mutignani M, Runfola M, Scarfone A, Mugno M, Panunzi S. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study. Aliment Pharmacol Ther. 2006;23(5):675–80.CrossRefGoogle Scholar
  23. 23.
    Topazian M, Camilleri M, Enders FT, Clain JE, Gleeson FC, Levy MJ, Rajan E, Nehra V, Dierkhising RA, Collazo-Clavell ML, et al. Gastric antral injections of botulinum toxin delay gastric emptying but do not reduce body weight. Clin Gastroenterol Hepatol. 2013;11:45–50.CrossRefGoogle Scholar
  24. 24.
    Intragastric injections of Botox for the treatment of obesity. In: 2017. Accessed 22 Oct 2017.
  25. 25.
    Cha R, Marescaux J, Diana M. Updates on gastric electrical stimulation to treat obesity: systematic review and future perspectives. World J Gastrointest Endosc. 2014;6(9):419–31.CrossRefGoogle Scholar
  26. 26.
    Lonys L, Vanhoestenberghe A, Julémont N, Godet S, Delplancke MP, Mathys P, Nonclercq A. Silicone rubber encapsulation for an endoscopically implantable gastrostimulator. Med Biol Eng Comput. 2015;53(4):319–29.CrossRefGoogle Scholar
  27. 27.
    Neto MG, Rajagopalan H, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L. 829 Endoscopic duodenal mucosal resurfacing improves glycemic and hepatic parameters in patients with type 2 diabetes: data from a first-in-human study. Gastroenterology. 2016;150(4):S174.CrossRefGoogle Scholar
  28. 28.
    Rajagopalan H, Cherrington AD, Thompson CC, Kaplan LM, Rubino F, Mingrone G, Becerra P, Rodriguez P, Vignolo P, Caplan J, Rodriguez L. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.CrossRefGoogle Scholar
  29. 29.
    Effect of DMR using the Revita system in the treatment of type 2 diabetes (T2D). In: 2017. Accessed 30 Oct 2017.
  30. 30.
    Machytka E, Buzga M, Ryou M, Lautz DB, Thompson CC. 1139 Endoscopic dual-path enteral anastomosis using self-assembling magnets: first-in-human clinical feasibility. Gastroenterology. 2016;150(4):S232.CrossRefGoogle Scholar
  31. 31.
    Machytka E, Buzga M, Lautz DB, Ryou M, Simonson D, Thompson CC. 103 A dual-path enteral bypass procedure created by a novel incisionless anastomosis system (IAS): 6-month clinical results. Gastroenterology. 2016;150(4):S26.CrossRefGoogle Scholar
  32. 32.
    Machytka E, Bužga M, Zonca P, Lautz DB, Ryou M, Simonson DC, Thompson CC. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim results in subjects with obesity and diabetes. Gastrointest Endosc. 2017;86:904.CrossRefGoogle Scholar
  33. 33.
    Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: a systematic review. World J Gastroenterol: WJG. 2015;21(17):5359.CrossRefGoogle Scholar
  34. 34.
    Vrieze A, Van Nood E, Holleman F, Salojärvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6.CrossRefGoogle Scholar
  35. 35.
    Transplantation of microbes for treatment of metabolic syndrome & NAFLD. In: 2016. Accessed 22 Oct 2017.
  36. 36.
    Fecal microbiota transplantation for diabetes mellitus type II in obese patients. In: 2016. Accessed 22 Oct 2017.
  37. 37.
    Fecal microbiota transplantation for the treatment of obesity (FMT obesity). In: 2017. Accessed 22 Oct 2017.
  38. 38.
    Fecal microbiota transplant for obesity and metabolism. In: 2017. Accessed 22 Oct 2017.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Massachusetts General Hospital, Department of MedicineBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Brigham and Women’s Hospital, Division of Gastroenterology, Hepatology, and EndoscopyBostonUSA

Personalised recommendations